

SANOFI S.A.

ISIN: FR0000120578

WKN: 12057

Asset Class: Stock

Company

2024/05/03 17:35:27



Price

91.30

EUR

Difference

-0.65% (-0.60)

Contact Details

SANOFI

Tel: +33-1-53-77-40-00

--

Fax: +33-1-53-77-44-03

46, avenue de la Grande Armée
75017 ParisWeb: <http://www.sanofi.com>

E-mail: -

Company Profile

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2023		2022		2021	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
Current assets	30,655,000,000		34,026,000,000		30,564,000,000	
Common stock capital		2,530,000,000		2,522,000,000		2,527,000,000
Fixed assets	95,809,000,000		92,696,000,000		89,678,000,000	
Equity capital of a company		74,353,000,000		75,152,000,000		69,031,000,000
Cash and cash equivalents	8,710,000,000		12,736,000,000		10,098,000,000	
Accrued liabilities		5,262,000,000		5,822,000,000		6,430,000,000
Other assets	-		-		-	
Current liabilities		24,194,000,000		23,964,000,000		21,295,000,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		27,917,000,000		27,606,000,000		29,916,000,000
Different income		-		-		-
Other liabilities		4,696,000,000		3,182,000,000		2,907,000,000
Total assets	126,464,000,000	126,464,000,000	126,722,000,000	126,722,000,000	120,242,000,000	120,242,000,000

Balance notes

	2023	2022	2021
Accounting standard	IFRS	IFRS	IFRS
Employees	87,994	91,573	95,442
Equity ratio	59.04%	59.60%	57.70%
Debt-equity ratio	69.37%	67.80%	73.31%

Others

	2023	2022	2021
Tax Expense Rate	22.40%	19.25%	19.98%

Income statement

	2023	2022	2021
Turnover	43,070,000,000	42,997,000,000	37,761,000,000
Net income	5,400,000,000	8,371,000,000	6,223,000,000
EBIT	7,701,000,000	10,660,000,000	8,171,000,000
Operating income before taxes	7,153,000,000	10,422,000,000	7,798,000,000
Cash Flow	10,258,000,000	10,526,000,000	10,522,000,000
Net interest income	-548,000,000	-238,000,000	-373,000,000
Research and development expenses	6,725,000,000	6,705,000,000	5,689,000,000
Income taxes	1,602,000,000	2,006,000,000	1,558,000,000
Result from investments in subsidiaries, associates and other	-115,000,000	68,000,000	39,000,000
Revenues per employee	489,465	469,538	395,643

Board of Directors

Frédéric Oudéa	Chairman of Supervisory Board
Antoine Yver	Member of Supervisory Board
Emile Voest	Member of Supervisory Board
Wolfgang Laux	Member of Supervisory Board
Anne-Francoise Nesmes	Member of Supervisory Board
Barbara Lavernos	Member of Supervisory Board
Carole Ferrand	Member of Supervisory Board
Christophe Babule	Member of Supervisory Board
Fabienne Lecorvaisier	Member of Supervisory Board
Gilles Schnepf	Member of Supervisory Board
Lise Kingo	Member of Supervisory Board
Patrick Kron	Member of Supervisory Board
Rachel Duan	Member of Supervisory Board
Yann Tran	Member of Supervisory Board

Members of Management Board

Paul Hudson	Chairman of Managing Board
Brendan O'Callaghan	Member of Executive Committee
Brian Foard	Member of Executive Committee
Emmanuel Frenehard	Member of Executive Committee
Houman Ashrafian	Member of Executive Committee
Jean-Baptiste Chasseloup de Chatillon	Member of Executive Committee
Julie Van Ongevalle	Member of Executive Committee
Madeleine Roach	Member of Executive Committee
Natalie Bickford	Member of Executive Committee
Olivier Charneil	Member of Executive Committee
Roy Papatheodorou	Member of Executive Committee
Thomas Triomphe	Member of Executive Committee